Business Wire

NY-PHILIP-MORRIS-INTL

9.6.2021 10:29:09 CEST | Business Wire | Press release

Share
Philip Morris International Opens Third Funding Round of PMI IMPACT

Philip Morris International Inc. (PMI) (NYSE: PM) is calling for applications for the third funding round of PMI IMPACT , the global initiative supporting projects that aim to reduce or prevent illegal trade and counter its negative consequences for individuals, their families, and communities. The third funding round will support a broad range of projects designed to tackle the multifaceted and multinational illicit trade—ranging from illicit tobacco products and other consumer goods to counterfeiting of pharmaceuticals and electronics—across different geographies. Now open for submissions, applicants from public, private, or nonprofit organizations, including governmental organizations, international organizations, associations, academic institutions, and private companies, are encouraged to submit their project proposals.

“Illicit trade knows no borders, and effective measures are needed to fight this international threat, which is a top priority for PMI as it undermines all our efforts toward delivering a smoke-free future—a future that can one day be without cigarettes,” said Alvise Giustiniani, Vice President, Illicit Trade Prevention. “The pandemic has also impacted supply chains, border controls and cross-border interactions, and now, more than ever, we need programs like PMI IMPACT that exchange expertise and bring together organizations, ideas, and solutions to eradicate illegal trade.”

Bringing innovation and technological advancement in the fight against contraband and counterfeited goods is essential, especially in the midst of the COVID-19 pandemic. This is why PMI IMPACT will be open to projects aimed at limiting the threats of counterfeited and substandard vaccines, medicines, medical supplies, and personal protective equipment.

Applicants can be based anywhere in the world; however, all proposals must address the funding round theme and focus on one of the following topics:

  1. Border control
  2. Capacity building
  3. Restorative justice and victims’ protection
  4. Network engagements, awareness building, and international cooperation
  5. COVID-19 and the threat of illicit trade

Interested third parties can apply for the third funding round before one of the three deadlines for submission of applications:

  • First submission deadline: Sept. 15, 2021
  • Second submission deadline: Feb. 15, 2022
  • Third submission deadline: Aug. 15, 2022

PMI IMPACT is honored to be able to rely once again on the profound knowledge of the Expert Council , which is comprised of some of the world’s leading specialists in the field of law, human rights, anti-corruption, and technology. This council of external independent experts will play a central role in the evaluation and selection of the project proposals for the award of grants by PMI.

Navi Pillay, human rights advocate and member of the PMI IMPACT Expert Council, added: “PMI IMPACT offers a platform for organizations to bring resolutions to tackle the problematic reality of illegal trade. We are looking forward to evaluating the applications in the third funding round—the level of interest the initiative receives is truly remarkable. It is promising to see so many fantastic organizations working resolutely to fight illicit trade.”

Illegal trade remains a persistent and complex global problem. Its various forms—ranging from illicit tobacco trade to drugs, arms, and wildlife trafficking—are infinitely interlinked, with criminals exploiting large-scale smuggling routes and corrupt networks. Often operated by organized crime groups, illegal trade deprives governments and taxpayers of much needed revenues, takes business away from legitimate operators, deceives consumers with products of uncertain quality, and undermines society’s welfare and security.

Throughout the first and second funding rounds, PMI IMPACT has supported projects covering a range of activities making a lasting impact on illegal trade. We have worked with research programs to enhance knowledge on illegal trade, educational initiatives to improve public awareness of the issue, and we have helped fund the development of technological solutions to facilitate anti-illicit efforts. PMI had pledged USD 100 million to fund the first three rounds of grants; to date, PMI IMPACT has allocated a combined $48 million for the implementation of 60 projects in 30 countries as part of the initiative’s first and second funding rounds.

If you are interested in putting forward a proposal for PMI IMPACT’s third funding round, please contact the project office of PMI IMPACT at impact@pmi.com . To find out more information on how to apply, please visit www.pmi-impact.com .

Philip Morris International: Delivering a Smoke-Free Future

Philip Morris International (PMI) is leading a transformation in the tobacco industry to create a smoke-free future and ultimately replace cigarettes with smoke-free products to the benefit of adults who would otherwise continue to smoke, society, the company, its shareholders and its other stakeholders. PMI is a leading international tobacco company engaged in the manufacture and sale of cigarettes, as well as smoke-free products, associated electronic devices and accessories, and other nicotine-containing products in markets outside the U.S. In addition, PMI ships versions of its IQOS Platform 1 device and consumables to Altria Group, Inc. for sale under license in the U.S., where these products have received marketing authorizations from the U.S. Food and Drug Administration (FDA) under the premarket tobacco product application (PMTA) pathway; the FDA has also authorized the marketing of a version of IQOS and its consumables as a Modified Risk Tobacco Product (MRTP), finding that an exposure modification order for these products is appropriate to promote the public health. PMI is building a future on a new category of smoke-free products that, while not risk-free, are a much better choice than continuing to smoke. Through multidisciplinary capabilities in product development, state-of-the-art facilities and scientific substantiation, PMI aims to ensure that its smoke-free products meet adult consumer preferences and rigorous regulatory requirements. PMI's smoke-free product portfolio includes heat-not-burn and nicotine-containing vapor products. As of March 31, 2021, PMI's smoke-free products are available for sale in 66 markets in key cities or nationwide, and PMI estimates that approximately 14.0 million adults around the world have already switched to IQOS and stopped smoking. For more information, please visit www.pmi.com and www.pmiscience.com .

# # #

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Rimini Street Announces Fiscal Second Quarter 2026 Financial and Operating Results30.7.2026 22:03:00 CEST | Press release

Second Quarter Financial Highlights Include: Revenue of $111.1 million, up 6.7% year over year Adjusted Revenue of $108.0 million, up 10.0% year over year Remaining Performance Obligations (RPO) of $636.9 million, up 8.0% year over year Adjusted Annualized Recurring Revenue of $401.1 million, up 8.1% year over year Rimini Street, Inc., (Nasdaq: RMNI), a global provider of end-to-end enterprise software support, managed services and Agentic AI ERP innovation solutions, and the leading third-party support provider for Oracle, SAP and VMware software, today announced results for the fiscal second quarter ended June 30, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260730702735/en/ Rimini Street Announces Fiscal Second Quarter 2026 Financial and Operating Results “Second-quarter results and four consecutive quarters of improved growth metrics demonstrate strong demand for our core Rimini Support™ offering, increasing adop

Rimini Street Launches Rimini Govern™ for AI to Deliver Comprehensive AI Agent Governance, Security & Interoperability as a Service30.7.2026 22:01:00 CEST | Press release

The new service enables organizations to quickly and easily implement and operationalize a global, enterprise-wide governance, control, security and performance measurement solution for AI agent activity and workflows Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced the immediate availability of Rimini Govern™ for AI, the newest offering in the company’s Rimini Govern portfolio of Governance, Risk and Compliance (GRC) solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260730389723/en/ Rimini Street Launches Rimini Govern™ for AI to Deliver Comprehensive AI Agent Governance, Security & Interoperability as a Service The new managed service is delivered 24/7/365 through Rimini Street’s Global Command Centers by expert AI engineers to help organizations: Accelerate AI agent deployment Reduc

One Biosciences Announces Data Validating New Method for Single-Cell Transcriptomic Tumor Profiling from Clinical Pathology Samples30.7.2026 21:03:00 CEST | Press release

Sample-to-report workflow generating single-cell RNA expression profiles using routine FFPE pathology slides from four institutions validated across 88 specimens and six cancer types One Biosciences, a techbio company pioneering clinical-grade single-cell tumor profiling, today announced data establishing that single-cell RNA expression profiles can be generated from the standard, formalin-fixed paraffin-embedded (FFPE) pathology specimens obtained in routine cancer care using the company’s proprietary platform, OneMap™. The study, conducted with collaborators at Centre Léon Bérard, Hôpital Bichat–Claude Bernard, Institut Curie, and Memorial Sloan Kettering Cancer Center, was released as a preprint on BiorXiv. “Every tumor is a unique ecosystem of many different types of cells, some cancerous, some not. Single cell profiling enables us to understand what those cells are, what they’re doing and potentially how that may impact treatment outcomes,” said Helena Yu, MD, thoracic medical onc

ARIS Recognized as a Leader in First Gartner® Magic Quadrant™ for Digital Twin of an Organization Platforms, Believes This Reinforces Need for Trusted Governance and Control of Enterprise AI30.7.2026 18:00:00 CEST | Press release

ARIS, the process context platform enabling enterprise AI deployment, today announced its recognition as a Leader in the inaugural Gartner Magic Quadrant for Digital Twin of An Organization (DTO) Platforms – where it believes agentic AI, autonomous workflows, and enterprise governance converge. As enterprises move from AI experimentation to autonomous agent deployment, a critical challenge emerges: how do you safely scale autonomous AI when the enterprise lacks a unified digital twin – a single source of truth for processes, data, governance, and outcomes? Gartner describes the DTO as a dynamic software model that relies on operational and contextual data to understand how an organization operationalizes its business model, connects with its current state, responds to changes, deploys resources, simulates future states and delivers customer value. "Enterprises are rightfully ambitious about agentic AI and autonomous workflows," said Guillaume Bacuvier, CEO of ARIS. "But they're discove

Kingswood Capital Management Raises $4 Billion Across Two Oversubscribed Middle-Market Funds30.7.2026 17:00:00 CEST | Press release

The firm’s fourth institutional fundraise more than doubles its assets under management, reaching over $7 billion Kingswood Capital Management, L.P. (together with its affiliates, “Kingswood”), a Los Angeles-based investment firm focused on the middle-market, today announced the final closing of Kingswood Capital Opportunities Fund IV, L.P. (together with its parallel fund, “Fund IV”), with total capital commitments of $3.1 billion, as well as Kingswood Capital Opportunities Small Cap Fund I, L.P. (together with its parallel fund, “Small Cap Fund I”), with total capital commitments of $900 million. These funds more than double Kingswood’s total assets under management (“AUM”) to over $7 billion. Fund IV represents the fourth institutional fundraise in five years for Kingswood and is more than double the size of Fund III. Both Fund IV and the inaugural Small Cap Fund I were significantly oversubscribed in just five weeks. Fund IV exceeded its initial target of $2.25 billion, while Small

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye